374 related articles for article (PubMed ID: 30925910)
1. Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy.
Ying J; Zhou D; Gu T; Huang J; Liu H
BMC Cancer; 2019 Mar; 19(1):288. PubMed ID: 30925910
[TBL] [Abstract][Full Text] [Related]
2. Preoperative albumin-to-fibrinogen ratio predicts chemotherapy resistance and prognosis in patients with advanced epithelial ovarian cancer.
Yu W; Ye Z; Fang X; Jiang X; Jiang Y
J Ovarian Res; 2019 Sep; 12(1):88. PubMed ID: 31533857
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of pretreatment albumin-to-fibrinogen ratio in small cell lung cancer patients receiving first-line platinum-based chemotherapy.
Li Q; Li L; Wang Y; Xu C; Zou J
Heliyon; 2023 Sep; 9(9):e19225. PubMed ID: 37662747
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of pre-resection albumin/fibrinogen ratio in patients with non-small cell lung cancer: A propensity score matching analysis.
Chen S; Yan H; Du J; Li J; Shen B; Ying H; Zhang Y; Chen S
Clin Chim Acta; 2018 Jul; 482():203-208. PubMed ID: 29653085
[TBL] [Abstract][Full Text] [Related]
5. Fibrinogen/albumin ratio as a promising predictor of platinum response and survival in ovarian clear cell carcinoma.
Chen W; Shan B; Zhou S; Yang H; Ye S
BMC Cancer; 2022 Jan; 22(1):92. PubMed ID: 35062908
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
Wang J; Liu Y; Mi X; Shao M; Liu L
Ann Palliat Med; 2020 May; 9(3):967-978. PubMed ID: 32389020
[TBL] [Abstract][Full Text] [Related]
8. The Glasgow prognostic score as a prognostic factor in patients with advanced non-small cell lung cancer treated with cisplatin-based first-line chemotherapy.
Jiang AG; Lu HY
J Chemother; 2015 Feb; 27(1):35-9. PubMed ID: 24716851
[TBL] [Abstract][Full Text] [Related]
9. Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
Du G; Yang Y; Zhang Y; Sun T; Liu W; Wang Y; Li J; Zhang H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):893-904. PubMed ID: 23355038
[TBL] [Abstract][Full Text] [Related]
10. Prognostic nomogram based on pre-treatment HALP score for patients with advanced non-small cell lung cancer.
Gao S; Huang Q; Wei S; Lv Y; Xie Y; Hao Y
Clinics (Sao Paulo); 2024; 79():100371. PubMed ID: 38735175
[TBL] [Abstract][Full Text] [Related]
11. Albumin-to-fibrinogen ratio as a promising biomarker to predict clinical outcome of non-small cell lung cancer individuals.
Li SQ; Jiang YH; Lin J; Zhang J; Sun F; Gao QF; Zhang L; Chen QG; Wang XZ; Ying HQ
Cancer Med; 2018 Apr; 7(4):1221-1231. PubMed ID: 29533009
[TBL] [Abstract][Full Text] [Related]
12. Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib.
Fiala O; Pesek M; Finek J; Racek J; Minarik M; Benesova L; Bortlicek Z; Sorejs O; Kucera R; Topolcan O
Neoplasma; 2016; 63(3):471-6. PubMed ID: 26952513
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment to Posttreatment Hypoxia Inducible Factor-1α Ratios as a Potentially Predictive Marker for First-Line Treatment in Nonsmall Cell Lung Cancer Patients without Known Driver Mutations.
Hu M; Zhang T; Gu M; Li J; Zhang H; Wang Q; Hu F; Yang Y; Li B
Genet Test Mol Biomarkers; 2020 Dec; 24(12):798-803. PubMed ID: 33347392
[No Abstract] [Full Text] [Related]
14. Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy.
Karayama M; Inoue Y; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suda T
BMC Pulm Med; 2021 Dec; 21(1):409. PubMed ID: 34895201
[TBL] [Abstract][Full Text] [Related]
15. Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.
Kotake M; Miura Y; Imai H; Mori K; Sakurai R; Kaira K; Tomizawa Y; Minato K; Saito R; Hisada T
Chemotherapy; 2017; 62(4):205-213. PubMed ID: 28380484
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic Value of Pre-treatment Albumin/Fibrinogen Ratio in Patients with Diffuse Large B-cell Lymphoma].
Deng H; Zhang L; Wang HY; Huang MJ; Wei J; Zou XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):762-768. PubMed ID: 37356937
[TBL] [Abstract][Full Text] [Related]
17. Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese.
Xu JL; Hu LM; Huang MD; Zhao W; Yin YM; Hu ZB; Ma HX; Shen HB; Shu YQ
Asian Pac J Cancer Prev; 2012; 13(3):851-6. PubMed ID: 22631660
[TBL] [Abstract][Full Text] [Related]
18. Positive plasma cotinine during platinum-based chemotherapy is associated with poor response rate in advanced non-small cell lung cancer patients.
Dacosta-Noble P; Costantini A; Dumenil C; Dumoulin J; Helly de Tauriers P; Giraud V; Labrune S; Emile JF; Alvarez JC; Chinet T; Giroux Leprieur E
PLoS One; 2019; 14(7):e0219080. PubMed ID: 31260495
[TBL] [Abstract][Full Text] [Related]
19. The combination of plasma fibrinogen and neutrophil lymphocyte ratio (F-NLR) is a predictive factor in patients with resectable non small cell lung cancer.
Wang H; Zhao J; Zhang M; Han L; Wang M; Xingde L
J Cell Physiol; 2018 May; 233(5):4216-4224. PubMed ID: 29057536
[TBL] [Abstract][Full Text] [Related]
20. Albumin/fibrinogen ratio, a predictor of chemotherapy resistance and prognostic factor for advanced gastric cancer patients following radical gastrectomy.
Zhao G
BMC Surg; 2022 May; 22(1):207. PubMed ID: 35643493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]